Cambridge’s reputation as a global hub for life sciences has gained another boost with the official opening of Insmed Incorporated’s new research and development (R&D) facility, inaugurated in July 2025 by Her Royal Highness The Princess Royal.
Insmed, a U.S.-headquartered biopharmaceutical company, has expanded its UK footprint with a 17,000-square-foot laboratory on Cambridge’s Babraham Research Campus, dedicated to advancing its pioneering work in ‘synthetic rescue’ — an innovative approach to treating serious diseases with limited or no effective therapies.
During her visit, The Princess Royal toured the facility with Insmed’s Chair and CEO, Will Lewis, meeting scientists and learning about their research. The Cambridge team will lead development of Insmed’s synthetic rescue platform, which identifies targets outside of disrupted biological pathways that, when modulated, may restore health. By combining molecular and cell biology techniques with large-scale genetic data analysis, this approach could help correct the effects of underlying gene defects and enable damaged cells to recover.
“We are at a pivotal moment where new insights into the biology and genetics of serious diseases are opening new possibilities to identify and develop impactful treatments,” said Dr Tom Heightman, Insmed’s Senior Vice President of Research. “Our work in synthetic rescue was developed in Cambridge, and the opening of this site marks an exciting new chapter for our research here in the UK.”
The new facility will allow researchers across drug discovery, target discovery, and translational science to collaborate under one roof, streamlining the journey from early research to clinical application. Cambridge’s vibrant bioscience ecosystem was a key factor in Insmed’s decision to expand to the world-famous city. The Babraham Research Campus is home to more than 60 bioscience companies, co-located with the renowned Babraham Institute, providing a fertile environment for collaboration and innovation.
The Cambridge site joins Insmed’s existing research locations in New Jersey, New Hampshire, and San Diego, enabling close collaboration across continents. The company’s global R&D portfolio includes therapies for pulmonary and inflammatory diseases, with a treatment for a chronic lung condition already approved in the U.S., Europe, and Japan.
As The Princess Royal cut the ribbon, the opening not only marked a milestone for Insmed but also highlighted Cambridge’s growing importance on the world stage as a centre for breakthrough biomedical research.